As longevity biotech scales, new AI tools target the financial systems shaping which therapies reach patients.
Pharmaceutical R&D is often framed as a scientific challenge – how to identify targets, design molecules and navigate clinical trials – yet beneath this sits a quieter, less examined layer: how capital is actually allocated. Last week, Condor announced a $24 million Series A to build what it describes as the first financial intelligence platform for life sciences, aiming to bring real-time clarity to an industry still largely reliant on spreadsheets and fragmented systems.
The scale is not insignificant. With an estimated $300 billion spent annually on R&D, decisions about which programs proceed – and which quietly stall – are shaped not only by biology and clinical data, but by financial visibility, forecasting and operational coordination. Condor’s platform seeks to integrate clinical, operational and financial data into a single system, enabling companies to model costs, track performance and automate workflows that have historically been manual and slow.
Longevity.Technology: If biology is the engine of therapeutic progress, finance is still too often the handbrake; and in life sciences – where timelines are long, burn is high and uncertainty comes with the territory – that matters more than many would like to admit. The longevity sector in particular tends to speak the language of breakthroughs, platforms and moonshots, but therapies are not only lost in the lab or at the regulator’s desk – they can just as easily be strangled in a budget meeting by stale data, fractured systems and the enduring tyranny of the spreadsheet. There is something faintly absurd about an industry spending hundreds of billions on R&D while relying on financial infrastructure that can struggle to see, in real time, where value is being created or quietly destroyed; yet this is exactly the sort of invisible bottleneck that determines which programs advance and which are shelved. If we are serious about bringing more ambitious, preventive and aging-focused interventions to patients, then new science alone will not suffice – we also need new infrastructure, because a field cannot scale on brilliance at the bench while running its economics on administrative archaeology.
From spreadsheets to systems
Despite advances in AI-driven drug discovery and increasingly sophisticated trial design, the financial systems underpinning R&D have evolved more slowly. Clinical trial finances are often reconciled across disconnected contract research organization portals, enterprise resource planning systems and accounting tools – introducing delays, inconsistencies and, at times, blind spots.
Condor’s approach is to replace this patchwork with a unified platform built on proprietary clinical and financial ontologies – mapping relationships between trial protocols, site-level activity, vendor contracts and accounting rules. The platform is structured around three modules: Connect integrates data across the enterprise ecosystem into a single source of truth; Compass forecasts costs, models scenarios and surfaces risk as programs evolve; and Copilot automates accruals, reconciliations and monthly close tasks.
The company reports that its system is already managing over $19 billion in R&D spend, with customers including Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma and Madrigal Pharmaceuticals. Reported outcomes include forecast accuracy exceeding 90%, faster month-end close cycles and average budget savings of around 30%.
When information shapes outcomes
For founder and CEO Jennifer Kyle, the problem is not abstract. “I’ve seen firsthand that therapies save lives. Too often though, promising therapies are killed in budget meetings by data that’s months out of date. This isn’t a science problem; it’s a financial visibility problem,” she says. “That’s why I founded Condor – to give life sciences companies the financial clarity they need to bring life-changing therapies to patients. When the economics become clear, good therapies find their way to success.”
Her framing is notable in a sector accustomed to attributing failure primarily to scientific uncertainty. Here, the suggestion is more structural – that incomplete or delayed financial information can materially influence which trials proceed, particularly in areas where outcomes are long-term or less immediately monetizable.
For longevity-focused therapeutics, this dynamic is particularly acute. As interventions move up The Ten Levels of Longevity – from early-stage nutraceuticals (Levels 1-2) toward the high-stakes world of organ regeneration and systemic rejuvenation (Levels 7-9) – the capital requirements and trial durations swell. These advanced programs are the most vulnerable to the “stale data” Jennifer Kyle describes. When a Level 9 trial is running for years, the ability to see and predict spend in real-time isn’t just a matter of accounting; it’s a survival mechanism for the program itself. Without this visibility, the most ambitious systemic repairs risk being prematurely shelved not due to biological failure, but because of a lack of financial confidence during a long-haul clinical journey.
A new layer in the biotech stack
At the operational level, the appeal is immediate. “What drew me to Condor was the automation,” says Vince Barella, Director of Research and Development Accounting at Alumis. “Our team works with gigantic files, dozens of tabs, and thousands of rows of data. To automate all of that previously manual work is life changing. We expect Condor to boost our operating efficiency by thirty to forty percent.”
Investors, meanwhile, see something more foundational. As Alexander Leibowitz, Vice President at Insight Partners, puts it, Condor has built “the financial intelligence layer underneath clinical trial management, which is where some of the most consequential decisions in drug development are made.”
In that sense, financial infrastructure becomes part of the decision-making architecture of drug development itself – influencing portfolio strategy, risk tolerance and ultimately the number of programs that can be sustained. AI, here, is not accelerating discovery directly; it is shaping the conditions under which discovery is funded.
Scaling ambition
Condor plans to use its Series A funding to expand its platform capabilities and scale its team, drawing on experience from organizations including Medidata, BenchSci, Oracle, Benchling and Salesforce Life Sciences. As AI continues to permeate discovery and development, attention is now turning to adjacent systems that have remained comparatively static.
For an industry grappling with rising costs, increasing complexity and shifting expectations around prevention, the question is less whether innovation is needed, and more where it should be applied. Sometimes the constraint is not at the frontier of biology, but in the systems that decide what reaches it.
Quiet determinants
Not all bottlenecks announce themselves. Some sit in the background – embedded in processes, spreadsheets and delayed reports – shaping outcomes without ever appearing in a trial readout or regulatory filing. Addressing them may lack the drama of a new therapeutic modality, but their influence is difficult to ignore; and as longevity science pushes toward more complex, longer-term interventions, the systems that govern capital may prove as consequential as the science itself.
